Review of Zika virus treatment research summarizes drug repurposing, early-stage vaccines, and RNA-cleavage approaches
Three approaches to treatment and prevention research
A review summarizing research on drug repurposing for Zika virus infection, vaccines in early clinical development, and viral RNA-targeting technologies was published in the journal Virusdisease in March 2026. The authors describe the antiviral potential of existing drugs, the safety and immunogenicity of vaccine candidates, and studies of RNA cleavage in infected cells. The paper synthesizes existing research rather than reporting new trial results in patients, so the level of evidence provided by each approach should be distinguished.
Zika virus is associated with Guillain–Barré syndrome in adults and congenital abnormalities in newborns. As the rationale for development, the authors state that no drug had been approved to treat Zika infection as of the time the paper was written. This describes the status covered by the review and does not reflect a check of whether any drugs have been approved since then.
Existing drugs and host and viral targets
Drug repurposing is a strategy for evaluating existing drugs as candidates to treat other diseases. The review describes niclosamide, favipiravir, and chloroquine as candidates with antiviral potential. Targets studied include viral proteins and their precursors and complexes, as well as pathways involving host-cell kinases, glucose transporters, and NMDA receptors.
This summarizes several research approaches; it does not mean that all three drugs simultaneously inhibit all the listed targets. The abstract does not provide experimental conditions, control groups, effect sizes, or treatment durations for each drug. It is therefore difficult to determine the candidates’ relative merits or their therapeutic effects in patients with Zika infection from this material alone.
Vaccine immune responses and preventive efficacy are different assessments
The vaccine candidates mentioned are VRC-ZKADNA090-00-VP, AGS-v, and mRNA-1325. The authors summarize them as having entered early-stage clinical trials and shown acceptable safety and immunogenicity profiles. Immunogenicity refers to the ability to induce an immune response and is distinct from actually preventing infection or disease.
The provided abstract does not report participant numbers or characteristics, control groups, follow-up periods, adverse-event frequencies, or preventive efficacy figures. Observations in early clinical trials therefore cannot be taken to establish the safety needed for broad use or preventive efficacy. The abstract also provides no evidence that safety for pregnant women and fetuses has been established.
Directly targeting viral RNA in infected cells
The review describes research using a CRISPR-Cas13b approach to cleave single-stranded Zika virus RNA inside infected cells. The finding supported by the abstract is that viral RNA was directly targeted and cleaved. This cannot be described as a treatment that alters human DNA or as a therapy proven effective in patients.
The abstract does not report the degree of viral replication inhibition resulting from RNA cleavage, experimental conditions, or clinical trial results. Further evidence remains to be established between observing RNA cleavage and demonstrating a therapeutic effect.
Safety during pregnancy is an important development challenge
In view of the association between Zika virus and congenital abnormalities in fetuses, the authors emphasize evaluating the safety of drugs under development during pregnancy. Antiviral activity or an immune response can inform a candidate’s development potential, but clinical efficacy and safety for pregnant women and fetuses must each be validated. The review abstract helps identify research directions but does not provide a basis for predicting when a treatment or vaccine might become available for practical use.
The research was summarized based on the provided Europe PMC bibliographic record and abstract.
Zika virus has been a significant cause of neurovirulence in humans, posing a global health concern due to its association with Guillain-Barré syndrome in adults and congenital birth defects in neonates. Despite its re-emergence in the 2015-16 outbreaks, there is no approved treatment for Zika virus infection to date, making it a pressing concern. Recent efforts in drug repurposing and viral vaccine development offer a promising roadmap to mitigate Zika virus infections. Investigational molecules commonly target viral proteins, protein precursors, and complexes, and interfere with host pathways involving cellular kinases, glucose transporters, and NMDA receptors. Repurposed drug candidates like niclosamide, favipiravir, and chloroquine exhibit promising antiviral potential. In parallel, anti-ZIKV vaccines like VRC-ZKADNA090-00-VP, AGS-v, and mRNA-1325 have progressed to early-phase clinical trials, achieving acceptable safety and immunogenic profiles. CRISPR-Cas13b-based genome editing has also been successfully demonstrated to cleave Zika virus ssRNA in infected cells. This review elucidates the pathogenesis of Zika virus infection and provides an in-depth overview of current strategies and research aimed at targeting host and viral factors to achieve successful therapeutic outcomes. The review also underscores the importance of safety evaluation of developmental drugs in pregnancy due to the strong association between ZIKV and fetal birth defects.
The practical value of this review is that it organizes Zika treatment and prevention research into development pathways involving drug repurposing, vaccines, and viral RNA targeting. Researchers in the biosciences can use it as a starting point for examining the experimental systems, control groups, endpoints, and safety data in individual studies. RNA cleavage in cells, immune responses in early clinical trials, and therapeutic or preventive effects in patients constitute different evidence and should not be treated as equivalent achievements when comparing candidates. Because risks to pregnant women and fetuses are especially important in this disease, antiviral potential should be assessed alongside safety during pregnancy. The abstract, however, contains no quantitative comparative data, making it difficult to prioritize the development of any particular candidate.